Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

The National Register of Antipsychotic Medication in Pregnancy (NRAMP)Unknown
NCT00686946N/AUpdated Nov 28, 2023
Sponsor: The Alfred
Pregnancy · Mental Disorders
Australia
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and SupportUnknown
NCT06148610N/AUpdated Nov 28, 2023
Sponsor: Fonds de Dotation HTC Project
Hematologic Diseases · Bone Marrow Transplantation · Hematopoietic Stem Cell Transplantation
France
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible PatientsCompleted
NCT03677596Phase 4Updated Nov 22, 2023
Sponsor: Pfizer
Leukemia · Precursor b-Cell Lymphoblastic Leukemia-Lymphoma · ACUTE LYMPHOBLASTIC LEUKEMIA
United States, Hungary, India, Poland, Singapore +3 more
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and OlderCompleted
NCT04648241Phase 3Updated Nov 22, 2023
Sponsor: Pfizer
Tick-Borne Encephalitis
Japan
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid ArthritisCompleted
NCT00938587Phase 2Updated Nov 22, 2023
Sponsor: Pfizer
Rheumatoid Arthritis
United States, Czechia, Hong Kong, Hungary, Russia +8 more
Axitinib Therapy Management StudyWithdrawn
NCT04555603N/AUpdated Nov 21, 2023
Sponsor: Pfizer
Renal Cell Carcinoma
United States
Actigraphy Improvement With Voxelotor (ActIVe) StudyCompleted
NCT04400487Phase 4Updated Nov 21, 2023
Sponsor: Pfizer
Sickle Cell Disease · Sickle Cell Anemia
United States
Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCDTerminated
NCT04247594Phase 2Updated Nov 21, 2023
Sponsor: Pfizer
Sickle Cell Disease
United Kingdom
A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With AvelumabCompleted
NCT03409458Phase 1, Phase 2Updated Nov 18, 2023
Sponsor: Promontory Therapeutics Inc.
Non-Small Cell Lung Cancer (NSCLC)
United States, Switzerland
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminated
NCT03904251Phase 1Updated Nov 18, 2023
Sponsor: Jonsson Comprehensive Cancer Center
Acute Myelogenous Leukemia
United States
Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)Available
NCT05466578N/AUpdated Nov 15, 2023
Sponsor: Pfizer
Severe Uncontrolled Atopic Dermatitis
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial FibrillationCompleted
NCT01938248Phase 4Updated Nov 15, 2023
Sponsor: Population Health Research Institute
Atrial Fibrillation · Stroke
United States, Belgium, Canada, Czechia, Denmark +8 more
Varenicline In-Patient StudyCompleted
NCT01413516Phase 2Updated Nov 14, 2023
Sponsor: Stanford University
Smoking Cessation
United States
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.Completed
NCT01774721Phase 3Updated Nov 14, 2023
Sponsor: Pfizer
Non-small Cell Lung Cancer With EGFR-Activating Mutations
China, Hong Kong, Italy, Japan, Poland +2 more
Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled SyringeCompleted
NCT03034044N/AUpdated Nov 13, 2023
Sponsor: Pfizer
Factor VIII Deficiency, Congenital · Factor 8 Deficiency, Congenital · Autosomal Hemophilia A · Classic Hemophilia
A Target Occupancy Study With Ritlecitinib.Completed
NCT05128058Phase 1Updated Nov 13, 2023
Sponsor: Pfizer
Healthy
United States
OPALINE : A Study Of Morbidity And Mortality At 2 YearsCompleted
NCT02264665N/AUpdated Nov 13, 2023
Sponsor: Pfizer
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
France
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC PatientsCompleted
NCT01934452N/AUpdated Nov 13, 2023
Sponsor: Pfizer
Complete Remission in Renal Cell Carcinoma
France
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerCompleted
NCT03054363Phase 1, Phase 2Updated Nov 13, 2023
Sponsor: University of Colorado, Denver
Breast Cancer
United States
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection FractionTerminated
NCT05139615Phase 2Updated Nov 9, 2023
Sponsor: Pfizer
Acute Heart Failure With Reduced Ejection Fraction
United States, Germany, Greece, Poland, Serbia
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.Withdrawn
NCT05905341Phase 1Updated Nov 8, 2023
Sponsor: Pfizer
Breast Cancer · Ovarian Cancer · Liposarcoma · Non-small Cell Lung Cancer (NSCLC)
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in BrazilCompleted
NCT05052307N/AUpdated Nov 7, 2023
Sponsor: Hospital Moinhos de Vento
Covid19
Brazil
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in BrazilCompleted
NCT05403307N/AUpdated Nov 7, 2023
Sponsor: Hospital Moinhos de Vento
COVID-19
Brazil
Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus ErythematosusCompleted
NCT03142711N/AUpdated Nov 7, 2023
Sponsor: Lupus Research Alliance
SLE · Lupus Erythematosus, Systemic · Systemic Lupus Erythematosus
United States, Canada
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)Terminated
NCT02616185Phase 1Updated Nov 2, 2023
Sponsor: Pfizer
Prostatic Neoplasms
United States

Previous page Next page